Crossmark

Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib

Crossref DOI link: https://doi.org/10.1007/s11523-017-0528-z

Published Online: 2017-10-24

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

van Erp, Anke E. M. https://orcid.org/0000-0002-8694-922X
Hillebrandt-Roeffen, Melissa H. S.

van Houdt, Laurens

Fleuren, Emmy D. G.

van der Graaf, Winette T. A.

Versleijen-Jonkers, Yvonne M. H.
Funding

Funding for this research was provided by:

Novartis
License Information

License valid from 2017-10-24